title: Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene status.
authors.affiliation: Department of Medical Oncology, Regional Cancer and Blood Service, Auckland City Hospital, Auckland, New Zealand. reubenb@adhb.govt.nz
authors.forename: Reuben J
authors.initials: RJ
authors.lastname: Broom
authors.forename: Imogen
authors.initials: I
authors.lastname: Caldwell
authors.forename: Fritha
authors.initials: F
authors.lastname: Hanning
authors.forename: Peter
authors.initials: P
authors.lastname: Fong
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Deva
authors.forename: Paul
authors.initials: P
authors.lastname: Oei
mesh_terms: D017766:Acid Anhydride Hydrolases / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000235:genetics / Q000556:secondary*; D000068338:Everolimus; D017353:Gene Deletion; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007580:Jejunal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000235:genetics / Q000556:secondary*; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D011859:Radiography; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics*; D000099170:Bis(5'-adenosyl)triphosphatase
chemical_list: D017766:Acid Anhydride Hydrolases; D000970:Antineoplastic Agents; D000068338:Everolimus; D009363:Neoplasm Proteins; D020123:Sirolimus; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D000099170:Bis(5'-adenosyl)triphosphatase; C497446:VHL protein, human